- Global Pharma News & Resources

Eckert & Ziegler Reorganizes its Production Sites

Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Real Estate
Eckert & Ziegler Reorganizes its Production Sites

05-March-2020 / 20:24 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

- Sale of Belgian special purpose property initiated
- One-off income expected

Berlin, 5 March 2020. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) will reorganize its global network of radiopharmaceutical production sites and in this context sell a special property in Seneffe, Belgium. A corresponding agreement was notarised today- and, in addition to the sale of the building, also includes the transfer of the handling license and liability for any dismantling obligations. The transfer is subject to customary market conditions precedent. The necessary conditions include in particular the approval of the Belgian supervisory authority. The transfer and the associated effects on the balance sheet will only become effective once the supervisory authority has issued a positive decision.

If the authority approves the transfer as requested, this would result in a release of the disposal reserves previously held for the Belgian production building. This change in the balance sheet would result in a one-off income of 2.7 Mio. EUR for Eckert & Ziegler.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138,,

Information and Explanation of the Issuer to this News:

With the merger of the Belgian prostate implant specialist IBt in 2008, Eckert & Ziegler BEBIG SA took over a production site where cyclotrons were used to produce precursors for low-level radioactive implants. Since new production sites are planned in Asia and North America as part of a realignment and globalization of the Pharmaceuticals division, Eckert & Ziegler is now divesting from this special property.

05-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
13125 Berlin
Phone: +49 30 941084-138
Fax: +49 30 941084-112
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 991105

End of Announcement DGAP News Service

Editor Details

Last Updated: 05-Mar-2020